Chinese-owned companies manufacture vaccine components and therapeutics for Western countries, but they do so primarily through a business model called contract manufacturing rather than selling their own branded vaccines.Instead of buying a finished Chinese vaccine (like Sinovac), Western pharmaceutical companies hire Chinese Contract Development and Manufacturing Organizations (CDMOs) to formulate, cultivate, or package specific parts of their proprietary products.The industry operates through several specific mechanisms:

The Global "WuXi" ConglomerateThe most prominent example is WuXi Biologics (and its sister company WuXi AppTec), a massive Chinese global biotech contractor.

The $3 Billion Vaccine Deal: Through its subsidiary WuXi Vaccines, the company signed a massive 20-year, $3 billion contract with an undisclosed "global vaccine leader" to build a dedicated facility to manufacture drug substances and products for a major Western vaccine.

Therapeutics and Manufacturing:

Beyond vaccines, WuXi facilities in both China and the West routinely manufacture the complex proteins and monoclonal antibodies used in many prominent Western medications.2.

Commercial Partnerships for Global Markets

Western pharmaceutical giants frequently partner with Chinese manufacturers to co-develop or scale up production. For instance, GlaxoSmithKline (GSK) has an extensive commercial partnership with the Chinese leading manufacturer Zhifei to co-commercialize and scale production for vaccines like the Respiratory Syncytial Virus (RSV) vaccine.

Supply Chain Dependencies

While the active biological ingredient (the antigen) of a Western vaccine is rarely fully produced by a Chinese company for the U.S. market, China dominates the upstream chemical supply chain:

Raw Chemical Precursors: China produces the vast majority of raw starter chemicals, amino acids, and inactive stabilizers used globally to stabilize vaccines during production.

Ancillary Hardware: A large percentage of the physical glass vials, syringe plungers, and sterile packaging used by Western drugmakers is sourced from factories in China.Increasing Western ScrutinyThis deep manufacturing integration has become a major political flashpoint in the United States and Europe. The U.S. government has pushed forward legislative measures—such as the BIOSECURE Act—specifically aimed at limiting the reliance of U.S. pharmaceutical companies on certain Chinese biotech entities like WuXi over national security and supply chain vulnerabilities. In response, many of these contractors have aggressively built or acquired factories outside of mainland China—such as in Switzerland, Singapore, and the United States—to ensure they can legally continue supplying Western drug companies.